High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial.
Jun Mitsui, Takashi Matsukawa, Yukari Uemura...
https://pubmed.ncbi.nlm.nih.gov/37256098/Actively Recruiting
Led by Tokyo University · Updated on 2026-03-04
140
Participants Needed
12
Research Sites
N/A
Total Duration
Researchers are evaluating whether MSA-01, a highly bioavailable form of coenzyme Q10 ubiquinol, can slow the progression of multiple system atrophy MSA, a progressive neurodegenerative disorder with no established disease-modifying treatment. This multicenter, randomized, double-blind, placebo-controlled phase III study aims to assess the safety and effectiveness of MSA-01 compared to placebo in patients with MSA. The primary focus is on changes in motor impairment using the Unified Multiple System Atrophy Rating Scale UMSARS Part 2 score over one year. Participants will be randomly assigned to receive either oral MSA-01 or a placebo daily for 52 weeks. The study includes regular clinic visits for safety and efficacy assessments throughout the treatment period. Patients are asked to record their medication use and any side effects in a diary to help monitor their experience with the study drug or placebo. During the study, participants will undergo evaluations using clinical scales including UMSARS Part 1 and Part 2, the Barthel Index, and the Scale for the Assessment and Rating of Ataxia SARA. Safety assessments will be conducted regularly, and researchers will analyze data using statistical models to compare progression between groups. The total participation duration is about one year, with a focus on assessing changes from baseline to Week 52.
CONDITIONS
MSA-01 in Multiple System Atrophy
J
Jun Mitsui
I
Ikue Wada
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tokyo University
Lead Sponsor
Nobelpharma
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 52 weeks
Participants receive oral MSA-01 or placebo to evaluate the effect on Multiple System Atrophy symptoms.
Regular visits during the 52-week treatment period
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jun Mitsui, Takashi Matsukawa, Yukari Uemura...
https://pubmed.ncbi.nlm.nih.gov/37256098/Tokyo University
Lead Sponsor
Nobelpharma
Collaborating Sponsor